British Journal of Cancer

FIGURES AND TABLES

FROM:

A phase 1 study of tazarotene in adults with advanced cancer

P H Jones, R D Burnett, I Fainaru, P Nadolny, P Walker, Z Yu, D Tang-Liu, T S Ganesan, D C Talbot, A L Harris and G J S Rustin

BACK TO ARTICLE
Figure 1 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Figure 1.

(A) Plasma concentrations (meanplusminuss.e.m.) of tazarotenic acid following oral administration of 1.4 mg tazarotene in six cancer patients on day 0. (B) Plasma concentrations (meanplusminuss.e.m.) of tazarotenic acid following oral administration of 25.2 mg tazarotene in seven cancer patients on day 0. (C) Dose-normalised (1 mg) plasma concentrations (meanplusminuss.e.m.) of tazarotenic acid following oral administration of 1.4 mg tazarotene in six cancer patients on day 0. (D) Dose-normalised (1 mg) plasma concentrations (meanplusminuss.e.m.) of tazarotenic acid following oral administration of 25.2 mg tazarotene in seven cancer patients on day 0. (E) Dose-normalised (1 mg) plasma concentrations (meanplusminuss.e.m.) of tazarotenic acid following oral administration of 1.4 mg tazarotene in six cancer patients at week 4. (F) Dose-normalized (1 mg) plasma concentrations (meanplusminuss.e.m.) of tazarotenic acid following oral administration of 25.2 mg tazarotene in five cancer patients at week 4.

Full figure and legend (57K)
Table 1 - Summary of demographic and disease characteristics - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Table 1 - Summary of demographic and disease characteristics.

Full table
Table 2 - Summary of trial outcome and tazarotene dose levels (mg[thinsp]day-1) - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Table 2 - Summary of trial outcome and tazarotene dose levels (mg day-1).

Full table
Table 3 - Symptomatic adverse events and biochemical abnormalities of frequency[ge]10%, related to tazarotene treatment - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Table 3 - Symptomatic adverse events and biochemical abnormalities of frequencygreater than or equal to10%, related to tazarotene treatment.

Full table
Table 4 - Toxicities at or above grade 2 and their time of onset - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Table 4 - Toxicities at or above grade 2 and their time of onset.

Full table
Table 5 - Summary of the pharmacokinetic parameters of tazarotenic acid following single-dose oral administration of Tazarotene on day 0 and at 12 weeks - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Table 5 - Summary of the pharmacokinetic parameters of tazarotenic acid following single-dose oral administration of Tazarotene on day 0 and at 12 weeks.

Full table
BACK TO ARTICLE